TOP STORIES

• COMMENTARY Delving into Potential Implications of Envisaged Price Revision Overhaul
  September 12, 2022

• ORGANIZATION FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
  September 9, 2022

• BUSINESS Lagevrio’s Normal Distribution to Start from Sept. 16: MSD
  September 9, 2022

• ACADEMIA University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
  September 8, 2022

• REGULATORY Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
  September 8, 2022

• ORGANIZATION Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
  September 7, 2022

• BUSINESS Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
  September 7, 2022

• REGULATORY MHLW Study Group to Ponder Support Measures for Stable Generic Supplies
  September 6, 2022

• ORGANIZATION Chuikyo Payer Rep Eyes 5%-Plus Discrepancy Threshold or Broader Coverage: 2023 Off-Year Re-Pricing
  September 5, 2022

• ACADEMIA Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
  September 5, 2022

• ORGANIZATION FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
  September 2, 2022

• REGULATORY Japan to Supply AstraZeneca’s Evusheld Only for COVID-19 Prevention
  September 2, 2022

• REGULATORY New Expert Panel on Drug Distribution and Pricing Boots Up; 2-Step Proposals Eyed for Off-Year Revision, 2024 Reform
  September 1, 2022

• ORGANIZATION JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
  August 31, 2022

• REGULATORY University of Tokyo Selected as Flagship R&D Site to Orchestrate Japan’s Vaccine Efforts: SCARDA Project
  August 31, 2022

• REGULATORY Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
  August 30, 2022

• REGULATORY AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
  August 30, 2022

• COMMENTARY Tussle in Japan Diabetes Market Heating Up; BI and Sumitomo Nip and Tuck for No. 1 Slot
  August 29, 2022

• REGULATORY Lilly’s Tirzepatide in Line for Approval as Early as September as Japan’s 1st GIP/GLP-1 Agent
  August 26, 2022

• REGULATORY Japan Approves Label Expansions for Lynparza, Ultomiris, Keytruda, Tagrisso, and More
  August 25, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 75
• 76
• 77
• 78
• 79
• 80
• 81
• 82
• 83
• …
• Next ›
• 最終 »